Insider Selling: Personalis (NASDAQ:PSNL) CFO Sells $69,748.00 in Stock

Personalis, Inc. (NASDAQ:PSNL) CFO Aaron Tachibana sold 4,982 shares of the business’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $14.00, for a total transaction of $69,748.00. Following the completion of the sale, the chief financial officer directly owned 198,833 shares in the company, valued at $2,783,662. This represents a 2.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Aaron Tachibana also recently made the following trade(s):

• On Friday, June 26th, Aaron Tachibana sold 51,251 shares of Personalis stock. The shares were sold at an average price of $13.18, for a total value of $675,488.18.
• On Thursday, June 4th, Aaron Tachibana sold 40,000 shares of Personalis stock. The stock was sold at an average price of $12.01, for a total value of $480,400.00.
• On Friday, May 29th, Aaron Tachibana sold 38,799 shares of Personalis stock. The shares were sold at an average price of $11.58, for a total value of $449,292.42.

Personalis Stock Performance

NASDAQ PSNL opened at $13.79 on Thursday. Personalis, Inc. has a 52 week low of $3.84 and a 52 week high of $14.18. The stock’s 50 day moving average price is $8.84 and its two-hundred day moving average price is $8.37. The stock has a market capitalization of $1.44 billion, a price-to-earnings ratio of -13.52 and a beta of 2.23.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). Personalis had a negative net margin of 148.11% and a negative return on equity of 43.52%. The business had revenue of $15.47 million during the quarter, compared to analyst estimates of $14.48 million. On average, equities research analysts forecast that Personalis, Inc. will post -1.06 EPS for the current year.

Analyst Upgrades and Downgrades

PSNL has been the topic of a number of research analyst reports. Wall Street Zen cut shares of Personalis from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. Morgan Stanley reduced their target price on Personalis from $10.00 to $9.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a report on Tuesday, April 21st. Finally, BTIG Research cut their price target on Personalis from $13.00 to $11.00 and set a “buy” rating for the company in a report on Monday, May 11th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Personalis presently has an average rating of “Moderate Buy” and an average target price of $11.00.

Institutional Investors Weigh In On Personalis

Hedge funds and other institutional investors have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd grew its position in Personalis by 76.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after buying an additional 1,479 shares in the last quarter. International Assets Investment Management LLC acquired a new stake in shares of Personalis during the 4th quarter worth $31,000. Legal & General Group Plc bought a new position in shares of Personalis in the second quarter worth $30,000. BNP Paribas Financial Markets raised its stake in Personalis by 406.4% in the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after purchasing an additional 5,177 shares in the last quarter. Finally, AQR Capital Management LLC bought a new stake in Personalis during the fourth quarter worth about $82,000. 61.91% of the stock is currently owned by institutional investors and hedge funds.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.